The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast ...

Alan Tan, MD, discusses factors influencing the choice of immunotherapy plus tyrosine kinase inhibitor vs dual IO in patients ...

The FDA granted fast track designation to 64Cu-SAR-bisPSMA for PET imaging of PSMA-positive prostate cancer lesions in ...

The panelist discusses how real-world evidence for CAR T in relapsed/refractory multiple myeloma shows promising efficacy but ...

Patients with AML aged 80 years and older face poor survival despite treatment advances, highlighting the need for improved, ...